CDEX Inc. is a technology company that develops chemical detection products to make the world safer. It has two divisions: the Medication Safety Division produces the ValiMed system to validate medications in healthcare settings, while the Security Division produces the ID2 line of products to detect illicit drugs for law enforcement. CDEX has experienced rapid revenue growth through expanding its commercial operations internationally. It expects continued growth by introducing new products and expanding into additional markets like brand protection.
EU MDR Preparation: Seize the Market Opportunity and Avoid the BottleneckApril Bright
The new EU Medical Device Regulation (MDR) is the single largest change to medical device regulations in Europe since the 1993 introduction of CE Marking. As grandfathering of existing products is not permitted, the new regulations affect all medical devices sold throughout Europe. There is a temptation for medical device companies to think that the transition arrangements through 1Q20 under MDR leave a considerable amount of time to ensure compliance. Research predicts that companies that do not address MDR early will suffer from potential bottlenecks among Notified Bodies for certification completion and capacity shortages by compliance professionals in the preparatory process. If you have not started to plan for the transition, now is the time to act. This presentation will take you through the main regulation changes and outline key requirements affecting manufacturers moving forward.
European MDR - Understanding Safety and Performance RequirementsKirsten Bertelsen
This presentation is the first of a series of short presentations by medicQA introducing key parts of the new MDR and their impact on medical device manufacturers.
The Top 10 Most Significant Changes Introduced by the New EU MDR (and how to ...Greenlight Guru
As most of you have likely heard, the EU's new Medical Device Regulations (MDR) went into effect earlier this year replacing the old MDD and setting in motion a three-year countdown for manufacturers to comply to continue selling in the European market.
You also likely have a lot of questions about what do these changes mean, how can you begin preparing, how will they affect your company, what are their greatest implications, etc.?
Specifically, this presentation covers:
-How much will the new Medical Device Regulation cost?
-Why did it need to happen and what is the new structure?
-What additional activities does a manufacturer have to carry out?
-What are the top 10 most significant changes?
-What is EUDAMED and how has its role changed?
-And much more...
Watch the presentation here: https://www.greenlight.guru/webinar/eu-mdr-most-significant-changes
Through practical case studies and industry specific analysis sessions, Medical Device UDIs & Traceability Forum Europe 2015 is geared around strengthening your regulatory infrastructure, maintaining productivity and ensuring ROI from your UDI projects.
View the full agenda here: bit.ly/MedicalDeviceUDI2015Agenda
Alternatively, email enquire@iqpc.co.uk or call +44 (0)207 036 1300 for a copy.
Insights about changes to the EU's MDR (Medical Device Regulations) by Ulf Grundmann, Partner, King & Spalding, August 17, 2020. Includes scope and definitions, classification and conformity assessment, placing a device on the EU marketin, UDI and EUDAMED, supply chain obligations, PMS, compliance and vigilance.
EU MDR Preparation: Seize the Market Opportunity and Avoid the BottleneckApril Bright
The new EU Medical Device Regulation (MDR) is the single largest change to medical device regulations in Europe since the 1993 introduction of CE Marking. As grandfathering of existing products is not permitted, the new regulations affect all medical devices sold throughout Europe. There is a temptation for medical device companies to think that the transition arrangements through 1Q20 under MDR leave a considerable amount of time to ensure compliance. Research predicts that companies that do not address MDR early will suffer from potential bottlenecks among Notified Bodies for certification completion and capacity shortages by compliance professionals in the preparatory process. If you have not started to plan for the transition, now is the time to act. This presentation will take you through the main regulation changes and outline key requirements affecting manufacturers moving forward.
European MDR - Understanding Safety and Performance RequirementsKirsten Bertelsen
This presentation is the first of a series of short presentations by medicQA introducing key parts of the new MDR and their impact on medical device manufacturers.
The Top 10 Most Significant Changes Introduced by the New EU MDR (and how to ...Greenlight Guru
As most of you have likely heard, the EU's new Medical Device Regulations (MDR) went into effect earlier this year replacing the old MDD and setting in motion a three-year countdown for manufacturers to comply to continue selling in the European market.
You also likely have a lot of questions about what do these changes mean, how can you begin preparing, how will they affect your company, what are their greatest implications, etc.?
Specifically, this presentation covers:
-How much will the new Medical Device Regulation cost?
-Why did it need to happen and what is the new structure?
-What additional activities does a manufacturer have to carry out?
-What are the top 10 most significant changes?
-What is EUDAMED and how has its role changed?
-And much more...
Watch the presentation here: https://www.greenlight.guru/webinar/eu-mdr-most-significant-changes
Through practical case studies and industry specific analysis sessions, Medical Device UDIs & Traceability Forum Europe 2015 is geared around strengthening your regulatory infrastructure, maintaining productivity and ensuring ROI from your UDI projects.
View the full agenda here: bit.ly/MedicalDeviceUDI2015Agenda
Alternatively, email enquire@iqpc.co.uk or call +44 (0)207 036 1300 for a copy.
Insights about changes to the EU's MDR (Medical Device Regulations) by Ulf Grundmann, Partner, King & Spalding, August 17, 2020. Includes scope and definitions, classification and conformity assessment, placing a device on the EU marketin, UDI and EUDAMED, supply chain obligations, PMS, compliance and vigilance.
Top 10 Network Operation Center Best Practices
In this free ebook you'll find tips
and best practices related to:
5 Essential tools NOC must have:
1. How to develop and maintain team knowledge and skills
2. Training new NOC Team
3. Improving communication and collaboration within and outside the NOC
4. Escalating, prioritizing, and handling problems
The investor presentation we used to raise 2 million dollarsMikael Cho
The investor presentation we used to raise 2 million dollars for ooomf.com (now pickcrew.com)
View the online version here: https://pickcrew.com/investors/
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
Access 2-healthcare company introduction deck - english - may 2018Access-2-Healthcare
Market Entry for Medical Technology / Medical Device companies, in Asia Pacific, Europe, US
#Commercialisation
#Healthcare
#Regulatory
#Quality
#SoftwareValidation / #Verification
#DueDiligence
#LicenseHolding
#Go-to-MarketStrategy
#MarketStudies
Access 2-healthcare , Company Introduction Deck - English - Aug 2017Access-2-Healthcare
Access-2-Healthacare helps small / medium sized medical technology companies gain market entry to various countries, business due diligence, quality, regulatory approvals, trade compliance, software testing, business partnership, product commercialisation
Top 10 Network Operation Center Best Practices
In this free ebook you'll find tips
and best practices related to:
5 Essential tools NOC must have:
1. How to develop and maintain team knowledge and skills
2. Training new NOC Team
3. Improving communication and collaboration within and outside the NOC
4. Escalating, prioritizing, and handling problems
The investor presentation we used to raise 2 million dollarsMikael Cho
The investor presentation we used to raise 2 million dollars for ooomf.com (now pickcrew.com)
View the online version here: https://pickcrew.com/investors/
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
Access 2-healthcare company introduction deck - english - may 2018Access-2-Healthcare
Market Entry for Medical Technology / Medical Device companies, in Asia Pacific, Europe, US
#Commercialisation
#Healthcare
#Regulatory
#Quality
#SoftwareValidation / #Verification
#DueDiligence
#LicenseHolding
#Go-to-MarketStrategy
#MarketStudies
Access 2-healthcare , Company Introduction Deck - English - Aug 2017Access-2-Healthcare
Access-2-Healthacare helps small / medium sized medical technology companies gain market entry to various countries, business due diligence, quality, regulatory approvals, trade compliance, software testing, business partnership, product commercialisation
Implant Sciences (OTCQB:IMSC) is the leader in next generation Explosives Trace Detection (ETD), and established counter-terrorism technology that detects and identifies threats from the small amounts left behind after a person handles explosives. Implant Sciences' security solutions are used worldwide for aviation, public transport, customs, air cargo, critical infrastructure, ports/ borders, and emergency response. The Company has thousands of units deployed to over 50 countries, and its trace detectors have been successfully used at the Sochi Olympics, Beijing Olympics, the Universiade Games, and the Special Olympics.
In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. With advanced capabilities including superior sensitivity, automatic internal calibration, rapid clear-down, ush button maintenance, and administration of trace detection. Company's handheld QS-H150 and desktop QS-B220 simplify the use, maintenance, and administration of trace detection. www.implantsciences.com
Digital Dose Inhaler Market PPT 2022: Industry Trends, Share, Size, Demand an...IMARC Group
Looking forward, the digital dose inhaler market value is projected to reach a strong growth during the forecast period (2022-2027).
More info:- https://www.imarcgroup.com/digital-dose-inhaler-market
Access 2-healthcare company introduction deck - English - Apr 2019Access-2-Healthcare
Market Entry for Medical Technology / Medical Device companies, in Asia Pacific, Europe, US
Market Launch of medtech products
Convert non-medtech company to create medtech portfolio
Regulatory framework for government agencies
#Commercialisation
#Healthcare
#Regulatory
#government
#Quality
#SoftwareValidation
#Verification
#Manufacturing
#MedtechInnovation
#DueDiligence
#LicenseHolding
#Go-to-Market Strategy
#MarketStudies
#RegulatoryFramework
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Tobias Schneck
As AI technology is pushing into IT I was wondering myself, as an “infrastructure container kubernetes guy”, how get this fancy AI technology get managed from an infrastructure operational view? Is it possible to apply our lovely cloud native principals as well? What benefit’s both technologies could bring to each other?
Let me take this questions and provide you a short journey through existing deployment models and use cases for AI software. On practical examples, we discuss what cloud/on-premise strategy we may need for applying it to our own infrastructure to get it to work from an enterprise perspective. I want to give an overview about infrastructure requirements and technologies, what could be beneficial or limiting your AI use cases in an enterprise environment. An interactive Demo will give you some insides, what approaches I got already working for real.
Securing your Kubernetes cluster_ a step-by-step guide to success !KatiaHIMEUR1
Today, after several years of existence, an extremely active community and an ultra-dynamic ecosystem, Kubernetes has established itself as the de facto standard in container orchestration. Thanks to a wide range of managed services, it has never been so easy to set up a ready-to-use Kubernetes cluster.
However, this ease of use means that the subject of security in Kubernetes is often left for later, or even neglected. This exposes companies to significant risks.
In this talk, I'll show you step-by-step how to secure your Kubernetes cluster for greater peace of mind and reliability.
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Jeffrey Haguewood
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows.
We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases.
This video focuses on the notifications, alerts, and approval requests using Slack for Bonterra Impact Management. The solutions covered in this webinar can also be deployed for Microsoft Teams.
Interested in deploying notification automations for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.
Encryption in Microsoft 365 - ExpertsLive Netherlands 2024Albert Hoitingh
In this session I delve into the encryption technology used in Microsoft 365 and Microsoft Purview. Including the concepts of Customer Key and Double Key Encryption.
Neuro-symbolic is not enough, we need neuro-*semantic*Frank van Harmelen
Neuro-symbolic (NeSy) AI is on the rise. However, simply machine learning on just any symbolic structure is not sufficient to really harvest the gains of NeSy. These will only be gained when the symbolic structures have an actual semantics. I give an operational definition of semantics as “predictable inference”.
All of this illustrated with link prediction over knowledge graphs, but the argument is general.
GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using Deplo...James Anderson
Effective Application Security in Software Delivery lifecycle using Deployment Firewall and DBOM
The modern software delivery process (or the CI/CD process) includes many tools, distributed teams, open-source code, and cloud platforms. Constant focus on speed to release software to market, along with the traditional slow and manual security checks has caused gaps in continuous security as an important piece in the software supply chain. Today organizations feel more susceptible to external and internal cyber threats due to the vast attack surface in their applications supply chain and the lack of end-to-end governance and risk management.
The software team must secure its software delivery process to avoid vulnerability and security breaches. This needs to be achieved with existing tool chains and without extensive rework of the delivery processes. This talk will present strategies and techniques for providing visibility into the true risk of the existing vulnerabilities, preventing the introduction of security issues in the software, resolving vulnerabilities in production environments quickly, and capturing the deployment bill of materials (DBOM).
Speakers:
Bob Boule
Robert Boule is a technology enthusiast with PASSION for technology and making things work along with a knack for helping others understand how things work. He comes with around 20 years of solution engineering experience in application security, software continuous delivery, and SaaS platforms. He is known for his dynamic presentations in CI/CD and application security integrated in software delivery lifecycle.
Gopinath Rebala
Gopinath Rebala is the CTO of OpsMx, where he has overall responsibility for the machine learning and data processing architectures for Secure Software Delivery. Gopi also has a strong connection with our customers, leading design and architecture for strategic implementations. Gopi is a frequent speaker and well-known leader in continuous delivery and integrating security into software delivery.
Key Trends Shaping the Future of Infrastructure.pdfCheryl Hung
Keynote at DIGIT West Expo, Glasgow on 29 May 2024.
Cheryl Hung, ochery.com
Sr Director, Infrastructure Ecosystem, Arm.
The key trends across hardware, cloud and open-source; exploring how these areas are likely to mature and develop over the short and long-term, and then considering how organisations can position themselves to adapt and thrive.
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualityInflectra
In this insightful webinar, Inflectra explores how artificial intelligence (AI) is transforming software development and testing. Discover how AI-powered tools are revolutionizing every stage of the software development lifecycle (SDLC), from design and prototyping to testing, deployment, and monitoring.
Learn about:
• The Future of Testing: How AI is shifting testing towards verification, analysis, and higher-level skills, while reducing repetitive tasks.
• Test Automation: How AI-powered test case generation, optimization, and self-healing tests are making testing more efficient and effective.
• Visual Testing: Explore the emerging capabilities of AI in visual testing and how it's set to revolutionize UI verification.
• Inflectra's AI Solutions: See demonstrations of Inflectra's cutting-edge AI tools like the ChatGPT plugin and Azure Open AI platform, designed to streamline your testing process.
Whether you're a developer, tester, or QA professional, this webinar will give you valuable insights into how AI is shaping the future of software delivery.
Builder.ai Founder Sachin Dev Duggal's Strategic Approach to Create an Innova...Ramesh Iyer
In today's fast-changing business world, Companies that adapt and embrace new ideas often need help to keep up with the competition. However, fostering a culture of innovation takes much work. It takes vision, leadership and willingness to take risks in the right proportion. Sachin Dev Duggal, co-founder of Builder.ai, has perfected the art of this balance, creating a company culture where creativity and growth are nurtured at each stage.
FIDO Alliance Osaka Seminar: The WebAuthn API and Discoverable Credentials.pdf
CDEX Inc Investors Presentation
1. – 1 –
CDEX Inc.
Investor Presentation
January 2009
INNOVATIONS FOR A SAFER WORLD
2. – 2 –
This presentation includes “forward-looking statements” as defined by the Securities and
Exchange Commission. These statements generally concern our plans, expectations and
objectives for future operations.
All statements, other than statements of historical facts, included in the presentation that address
activities, events or developments that we expect, believe or anticipate will or may occur in the
future are forward-looking statements. They are based on assumptions which we believe are
reasonable based on current expectations and projections about future events, industry
conditions and trends affecting our business.
However, whether actual results and developments will conform to our expectations and
predictions is subject to a number of risks and uncertainties which could cause actual results to
differ materially from those contained in the forward-looking statements. CDEX has no obligation
to update such forward looking statements.
Please refer to cautionary language provided in our SEC Form 10-K and Form 10-Q filings and
other public disclosures.
Cautionary language
4. – 4 –
We are a technology development company headquartered in Tucson, AZ,
specializing in advanced chemical detection.
We aim to make the world safer through our innovations.
Our vision drives us to:
Who we are
Introduce state-of-the-art products to the marketplace
Create a growing demand for our patented technologies
Increase our scientific knowledge and expertise to expand
our future products, services and markets
Reward our investors through a thriving, profitable and
growing business enterprise
Conduct business in a manner consistent with the fundamental beliefs of our
management team
5. – 5 –
CDEX possesses the assets of success:
Why we will succeed
PEOPLE
Skilled, inventive, resourceful, dedicated
Our core values direct our efforts
TECHNOLOGY
Patent-protected systems and technologies
Intellectual property beyond current applications
PRODUCTS
Designed to address significant problems with little competition
Clients and distributors are world class companies
Greater than 50% gross margins
VISION
We are driven by our vision to protect people, save lives
and make the world safer.
6. – 6 –
We are a global leader in Enhanced Photoemission Spectroscopy.
Our patented technologies are applied in chemical detection processes.
Our first products deal with:
Medication and drug validation
Illicit drug detection
Innovations for a safer world
We expect our proprietary systems to be applied in other fields and markets,
currently including:
Homeland security – including customs and border patrol
(explosives and hazardous chemical detection)
Brand protection and counterfeit drug identification
7. – 7 –
Our patented technologies create unique and commanding products
for many industries and markets:
Real-time chemical detection and medication validation capabilities
High reliability and accuracy in measurements
Our process is lower in cost to customers compared to other technologies.
We are building a substantial chemical/medication signature library
so that our systems can serve multiple uses.
Substance testing for security uses is non-intrusive and non-destructive:
– Samples and evidence are preserved, not destroyed or altered.
Our systems reduce potential errors in human interpretation.
Competing or alternative technologies require frequent calibration
and cleaning, resulting in down-time and lost productivity.
Superior CDEX products create market demand
8. – 8 –
Strategy and long-term goals
We possess intellectual property and proprietary processes with many
potential commercial applications.
In the future, we expect to:
Continue the global market expansion of our existing product lines
in the healthcare and security markets
Expand our exiting product lines to price point to additional market segments
Differentiate and distinguish our products in the market due to their
reliable, accurate, ease-of-use, quick, flexible and low-cost nature
Enhance our products and technologies with periodic updates
and refinements to improve their uses
Develop new applications using our existing technologies
Develop or purchase additional technologies for development, and
Exploit our competitive advantage with multiple products
in multiple markets
9. – 9 –
Strategy and long-term goals
As we ramp up and expand our capabilities, over time we expect to:
Increase the economies of scale of our business operations
Maintain our product sales margins, which currently
are above 50%
Improve our overhead costs (selling, general and administrative)
on a per-unit basis or as a percentage of revenue
Continue investing in R&D and patent applications based on
discovery and opportunity
Continue advancing our vision and global outreach to make our world safer
This year, we have transformed from a scientific R&D Company
to full-scale manufacturing, commercial and marketing operations.
10. – 10 –
We are a Company on the move.
In recent months, among our public announcements were:
Record year over year revenues for FYs 2007 and 2008
Record sales/leases of ValiMed™ units in FY08
Security Division’s introduction of ID2 Meth Scanner™ and
Narcolyzer™ product lines
Expansion of U.S. and international sales and marketing network,
and product shipments both domestic and abroad
TUV certification for our ValiMed medical product line
(TUV Rheindland of North America testing for European standards
for product safety and regulatory compliance)
Expansion of Medication Signature Library used in ValiMed systems
Company staff restructuring to accommodate growth:
– We established two divisions, Medication Safety and Security,
to strategically focus operations to specific market opportunity
Recent events
12. – 12 –
In FY08, we doubled the number
of hospital clients using ValiMed.
In Q4 08, we sold or leased
11 units.
We expect to sell or lease at least
25 units in the first half of 2009.
Medication Safety Division
We are dedicated to make healthcare settings safer by creating solutions
that eliminate errors in medication formulation and dosage.
Under the ValiMedTM brand, we offer products and services that
authenticate medicines quickly, easily and economically,
thereby preventing costly mistakes from harming patients.
13. – 13 –
The ValiMedTM System
We have received critical acclaim in reviews and thorough trials:
Independent testing and analysis confirms system capabilities
demonstrated by our R&D team.
TUV certification also confirms the safety, accuracy and reliability
of our systems.
A growing Medication Signature Library makes the system
all the more valuable:
Our technology has broad appeal across
the medical safety field
This library has proprietary and economic value
to us, as we work with individual companies
on creating unique signatures for their
exclusive use.
14. – 14 –
The ValiMedTM CCT
It has a full complement of validation capabilities
with more features than original ValiMed unit.
It is compatible with ValiMed software and utilizes
similar components.
This product has been introduced to both the US and international markets.
The CCT unit is the newest ValiMed model with additional features, a
smaller footprint and greater sensitivity.
15. – 15 –
Examples of ValiMedTM market size and potential
Approximate
HOSPITALS Number
U.S. and Canada 7,000
Europe 10,000
Middle East 1,000
Asia 3,500
Japan 9,000
Australia/New Zealand/Oceania 2,000
Total 32,500
OTHER MARKETS
Nursing homes
Long-term health care facilities
16. – 16 –
We expect to add to our sales and marketing force
on an ongoing basis going forward.
Medication Safety Division expansion plans
We have a growing affiliation with sales and marketing representatives
including an office in Paris, France, serving Europe and the Mid-East:
United States
North America
France
Italy
Spain
Portugal
United Kingdom
Kuwait
United Arab Emirates
Bahrain
Qatar
18. – 18 –
We are committed to make the public safer and more secure
by creating ways to identify illicit drugs and dangerous chemicals
quickly and easily.
Under the ID2 TM brand, we offer products and services with our proprietary
systems to assist law enforcement and others involved with public safety
and property inspection.
Security Division
19. – 19 –
The ID2 TM product line is the right tool for illegal drug detection to assist law
enforcement and other professions in contact with the public and public places.
The Meth Scanner is mobile, lightweight, hand-held, accurate and
reliable in the field.
In addition to law enforcement, we envision other markets
will take advantage of ID2 capabilities, including
– Property inspection services
– Schools, customs, border patrols and the military
are other potential markets that can benefit from
ID2 capabilities.
Our scientists are working on other hand-held detectors,
including one capable of identifying additional illegal
substances.
The ID2 Meth ScannerTM
20. – 20 –
The ID2 NarcolyzerTM product line is the right tool for illegal drug detection
to assist law enforcement, public safety and other professions.
Introduced in October 2008 at the CopsWest Convention in Ontario, CA
The Narcolyzer is based on the ValiMed CCT system architecture:
– With fewer technical requirements, its price point is lower.
For the customer, the operational cost
for drug analysis is a fraction of costs
of alternative chemical detection systems.
The ID2 NarcolyzerTM
21. – 21 –
Examples of ID2 TM market size and potential
Approximate
PRIMARY MARKETS Size
U.S. law enforcement agencies 20,000
U.S. school systems 15,000
Total domestic market size 35,000
22. – 22 –
Examples of ID2 TM market size and potential
OTHER MARKETS
Property inspection services
(homes, apartments, hotels, buildings, autos, etc.)
Child protective services organizations
U.S. customs and border patrol
Jails and prisons
HAZMAT teams
Airports
International markets for all of the above
23. – 23 –
As our capabilities increase, we envision product line extensions:
The Meth Scanner is our introductory illicit drug detector.
We anticipate future models could incorporate additional drug signatures.
The Narcolyzer demonstrates how the ValiMedTM CCT platform
can be re-configured to complement the ID2 product family.
Security Division expansion plan
Homeland security-related products could be an adjunct to the ID2 line
as part of our Security Division:
Detection of chemicals used in explosives is showing significant potential
at the R&D stage
Rapid expansion of our sales and marketing network is expected:
Our domestic and international expansion plans include sales and
marketing presence in many industries and market segments.
25. – 25 –
The patents, technology and systems successfully applied to the ID2 TM
and ValiMedTM product lines can be adapted to other products and markets:
Our enhanced photoemission spectroscopy capability can be harnessed
for many chemical identification purposes, including protecting brands
and identifying counterfeit products.
We can work with customers to create signatures of their proprietary
products and work with them to identify counterfeit substances.
According to the Organization of Economic Cooperation and Development,
as much as 15% of the world’s drug supply is counterfeit.
We expect that the importance of brand protection will increase over time,
and we believe our capability can be a leader in the detection of
counterfeit substances throughout the globe.
Brand protection is a new frontier
27. – 27 –
We are methodical and deliberate in our business planning and
operational execution.
Our objective is rapid expansion while prudently managing resources:
We are focused on sustained revenue growth
– Revenue grew over 50% in FYs 2007 and 2008
Maintaining product sales gross margins in excess of 50%
2008 was our transformational year, from R&D to full-scale
innovation, manufacturing and commercial operations.
Resource allocation for expanded marketing network expected
to foster continued revenue growth next year and beyond
Additional operations and corporate staff to bolster production,
order fulfillment, customer service, support, oversight and
compliance functions, with efficiencies anticipated as we grow
Our business plan is on track
28. – 28 –
We believe our proprietary domain will lead to new products and markets.
Our planning includes ongoing R&D and innovation activity:
– Additional patent applications
– Systems and capabilities upgrades to existing product line
– New products for new markets expected
Anticipated new products for future introduction:
– ID2 TM scanner with advanced capabilities
– Scanner with chemical detection for explosives
– Custom scanning devices for counterfeit substance detection
– Advanced product design/miniaturization
– Advanced ValiMedTM systems with additional features
and capabilities
Scalable manufacturing capability to right-size inventory and assembly
Preparing for expansion and growth
29. – 29 –
We expect multiple revenue streams from our operations:
Product sales
Product leases
Extended service contracts
Charges for proprietary and technical services, including software,
component and capabilities upgrades for existing products
ValiMedTM Medication Signature Library
– We currently have over 180 chemical signatures on file with more slated
– These signatures are sold to our clients for their use
– Custom signatures may be done for clients on a fee basis
ValiMedTM cuvette (chemical sample holder) sales
Revenue sources
30. – 30 –
In the future, we intend to issue earnings guidance or other operational
or financial forecasts.
We expect to analyze metrics and glean data from our commercial operations
experience over time.
This input will assist us with internal evaluations and
improved decision making.
We are focused on increasing revenues and attaining positive cash flows
from operations, which we currently expect to occur in 2009.
Comment on corporate guidance and forecasts
31. – 31 –
Our web site contains extensive information on our product line, technology
and capabilities, along with upcoming events, public disclosures and links
to other useful sites about the markets we aim to serve.
Visit our web site for complete information
www.cdexinc.com
33. – 33 –
We are a solid investment with a bright, promising future:
2008 was our transformational year from R&D to commercial operations.
Our business plan has expanded its focus into manufacturing, marketing
and sales while continuing our innovation and product creation efforts.
Our financial foundation is improving with increased revenues:
– Currently, we expect positive cash flows from operations in 2009.
We expect to maintain product sales gross margins exceeding 50%.
Our revenues and financial strength is expected to improve
through multiple product lines and market expansions.
Improved economies of scale expected as commercial operations expand.
Our net operating losses incurred during the R&D stage reduce
future income tax exposure.
Our intellectual property and products are unique in the marketplace.
We expect significant additional innovation, new product introductions
and existing product enhancements in the years ahead.
CDEX enters exciting next stage of performance
35. – 35 –
CDEX key facts
Corporate headquarters 4555 S. Palo Verde, Suite 123
Tucson, AZ 85714
520.745.5172
Web site www.cdexinc.com
Stock symbol CEXI
Stock trading venue OTCBB
Shares authorized ~100 million
Shares outstanding ~ 59 million
Inside ownership < 25%
Current full-time employees/consultants 20-25
Year incorporated 2001
Public stock listing 2004
Fiscal year-end October 31
State of incorporation Nevada
Accounting firm S.E. Clark & Co., PC
Tucson, AZ
36. – 36 –
Malcolm Philips, Chairman, President & CEO
www.cdexinc.com
CDEX Inc.INNOVATIONS FOR A SAFER WORLD
Thank you for your interest in